IG7 Stock Overview
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Memphasys Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.001 |
| 52 Week High | AU$0.012 |
| 52 Week Low | AU$0.001 |
| Beta | 0.73 |
| 1 Month Change | -60.00% |
| 3 Month Change | -75.00% |
| 1 Year Change | -89.47% |
| 3 Year Change | -97.62% |
| 5 Year Change | -91.67% |
| Change since IPO | -90.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| IG7 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -33.3% | -9.9% | -2.0% |
| 1Y | -89.5% | -14.9% | -0.3% |
Return vs Industry: IG7 underperformed the German Life Sciences industry which returned -14.9% over the past year.
Return vs Market: IG7 underperformed the German Market which returned -0.3% over the past year.
Price Volatility
| IG7 volatility | |
|---|---|
| IG7 Average Weekly Movement | 56.0% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: IG7's share price has been volatile over the past 3 months.
Volatility Over Time: IG7's weekly volatility has increased from 50% to 56% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | David Ali | www.memphasys.com |
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix, a device separates sperm from raw semen by electrophoresis process for use in human IVF procedures. In addition, the company’s product pipeline include ROSA, a rapid oxidative stress assay; Samson Device, rapid equine pregnancy prediction assay; SemPort, a system that allows transport of semen; and AI-Port.
Memphasys Limited Fundamentals Summary
| IG7 fundamental statistics | |
|---|---|
| Market cap | €6.63m |
| Earnings (TTM) | -€2.74m |
| Revenue (TTM) | €446.03k |
14.9x
P/S Ratio-2.4x
P/E RatioIs IG7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IG7 income statement (TTM) | |
|---|---|
| Revenue | AU$736.66k |
| Cost of Revenue | AU$26.15k |
| Gross Profit | AU$710.50k |
| Other Expenses | AU$5.23m |
| Earnings | -AU$4.52m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0033 |
| Gross Margin | 96.45% |
| Net Profit Margin | -613.81% |
| Debt/Equity Ratio | 57.0% |
How did IG7 perform over the long term?
See historical performance and comparison